Skip header and navigation

3 records – page 1 of 1.

Source
Ugeskr Laeger. 2008 Jan 21;170(4):215-7
Publication Type
Article
Date
Jan-21-2008
Author
Lars Søndergaard Johansen
Tom Howy Christensen
Anette Bendixen
Jørgen Nordling
Klaus Møller-Ernst Jensen
Henrik Kehlet
Author Affiliation
Herlev Hospital, Urologisk Afdeling, Rigshospitalet.
Source
Ugeskr Laeger. 2008 Jan 21;170(4):215-7
Date
Jan-21-2008
Language
Danish
Publication Type
Article
Keywords
Clinical Competence
Cystectomy - adverse effects - mortality - standards - statistics & numerical data
Denmark - epidemiology
Hospital Mortality
Humans
Length of Stay
Postoperative Complications - mortality
Registries
Reoperation
Treatment Outcome
Abstract
The organization and results after cystectomy in Denmark are unknown.
Based upon the Danish National Hospital Register and discharge notes, postoperative hospitalization, readmission within 30 days, re-operations and mortality after cystectomy in Denmark in the period January 1, 2000-December 31, 2005 were assessed.
There were 995 cystectomies with a median postoperative hospital stay of 18.9 days (including readmissions) and hospital mortality of 3.7%. The operations were performed in seven departments without difference in outcome between departments. Morbidity was observed in 58%, 16.8% of which were re-operated for wound or urinary diversion complications.
It is concluded that cystectomy should be performed in only five departments in Denmark, and the results suggest that an intensified multicenter collaboration should be initiated to improve outcome.
Notes
Comment In: Ugeskr Laeger. 2008 Jun 16;170(25):2260; author reply 226118581651
PubMed ID
18282449 View in PubMed
Less detail

High expression of karyopherin-a2 defines poor prognosis in non-muscle-invasive bladder cancer and in patients with invasive bladder cancer undergoing radical cystectomy.

https://arctichealth.org/en/permalink/ahliterature136932
Source
Eur Urol. 2011 May;59(5):841-8
Publication Type
Article
Date
May-2011
Author
Jørgen Bjerggaard Jensen
Pia Pinholt Munksgaard
Christoffer Mørk Sørensen
Niels Fristrup
Karin Birkenkamp-Demtroder
Benedicte Parm Ulhøi
Klaus Møller-Ernst Jensen
Torben F Ørntoft
Lars Dyrskjøt
Author Affiliation
Department of Urology, Aarhus University Hospital, Skejby, Denmark.
Source
Eur Urol. 2011 May;59(5):841-8
Date
May-2011
Language
English
Publication Type
Article
Keywords
Adult
Aged
Aged, 80 and over
Animals
Blotting, Western
COS Cells
Cell Line, Tumor
Cercopithecus aethiops
Cystectomy - adverse effects - mortality
Denmark
Disease-Free Survival
Female
Humans
Immunohistochemistry
Kaplan-Meier Estimate
Male
Middle Aged
Neoplasm Invasiveness
Predictive value of tests
Proportional Hazards Models
Risk assessment
Risk factors
Survival Rate
Time Factors
Tissue Array Analysis
Transfection
Treatment Outcome
Tumor Markers, Biological - genetics - metabolism
Up-Regulation
Urinary Bladder Neoplasms - genetics - metabolism - mortality - secondary - surgery
alpha Karyopherins - genetics - metabolism
Abstract
Conventional clinicopathologic risk factors have failed to accurately predict the prognosis of patients with bladder cancer (BC).
To evaluate karyopherin-a2 (KPNA2) expression as a progression marker in patients with non-muscle-invasive BC (NMIBC) treated by conservative methods and as a prognostic marker in patients with invasive BC undergoing radical cystectomy (RC).
Two different tissue microarrays were constructed, one with 234 primary Ta/T1 tumours from patients treated by transurethral resection of the bladder and one with 377 tumours from RC patients.
KPNA2 expression based on immunohistochemistry.
Risk of progression of Ta/T1 patients to muscle-invasive BC was estimated in clinical follow-up to progression or a minimum of 53 mo. Risk of recurrent disease and death following RC was estimated in clinical follow-up of a minimum of 24 mo in patients alive.
A high KPNA2 expression in Ta/T1 patients was significantly correlated with a higher risk of progression that was independent of conventional risk factors in multivariate analysis. In patients undergoing RC, a high KPNA2 expression was an independent predictor of poor prognosis. A high KPNA2 expression was correlated with a higher risk of visceral metastasis rather than lymphatic spread.
KPNA2 expression is a marker for progression of NMIBC and a prognostic marker in patients undergoing RC.
PubMed ID
21330047 View in PubMed
Less detail

Long-term risk of progression of carcinoma in situ of the bladder and impact of bacille Calmette-Guérin immunotherapy on the outcome.

https://arctichealth.org/en/permalink/ahliterature101389
Source
Scand J Urol Nephrol. 2011 Jul 27;
Publication Type
Article
Date
Jul-27-2011
Author
Karsten Zieger
Klaus Møller-Ernst Jensen
Author Affiliation
Department of Urology , Århus University Hospital Skejby, Århus , Denmark.
Source
Scand J Urol Nephrol. 2011 Jul 27;
Date
Jul-27-2011
Language
English
Publication Type
Article
Abstract
Abstract Objective. This study aimed to determine the long-term risk of cancer progression of carcinoma in situ (CIS) of the urinary bladder, and whether intravesical bacille Calmette-Guérin (BCG) immunotherapy can reduce the risk of progression of CIS.Material and methods. From a prospectively enrolled cohort of bladder cancer patients treated at Århus University Hospital Skejby, Denmark, between 1994 and 2008, all 163 cases with CIS in the bladder, and a history free of invasive bladder cancer (stage T1-4) at least 1 year prior to inclusion were included in the study. Results. Median follow-up was 51 (0-253) months for progression. Initial treatment consisted of transurethral resection (TUR) alone (109 patients) or TUR plus BCG (54 patients). Twenty-eight patients underwent delayed treatment with BCG. Twenty-one patients in the TUR-alone group (19%) and 42 BCG-treated patients (51%) were free of disease at the end of follow-up (p
PubMed ID
21793636 View in PubMed
Less detail